Clinical results of drug positive for chronic kidney disease


Astra Zeneca India (Astra Zeneca Pharma India Limited), led biopharmaceutical company has announced the full results from the clinical trials of it’s latest diabetes drug, Dapagliflozin.

According to a statement from the company Dapagliflozin shows significant benefits in reducing chronic kidney disease (CKD) progression in patients with and without type-2 diabetes.

This CKD benefit is over and above the superior anti-diabetic and heart failure benefits. Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that Dapagliflozin along with standard of care reduced the worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo in patients with chronic kidney disease (CKD).

The results were consistent in patients both with and without type-2 diabetes (T2D). Dr. Anil Kukreja, Vice President – Medical Affairs & Regulatory, Astra Zeneca India said, “ The DAPA-CKD trial which included 201 Indian patients with CKD into a global clinical study enrolling 4,304 patients, was able to show a benefit in patients with CKD.

Now this goes on show that Dapagliflozin which is effective in Type 2 Diabetes, select Heart Failure patients has demonstrated significant efficacy now even in Chronic Kidney Disease.”

Leave a Reply

Your email address will not be published. Required fields are marked *